Friday, January 4, 2013
TheraVida Inc., of Mountain View, Calif., reported Phase II results showing that lead candidate Tolenix (THVD-201) produced statistically significant improvements in overactive bladder and urge urinary incontinence symptoms over placebo, and patients experienced efficacy similar in magnitude to the maximum dose of active control Detrol (2 mg tolterodine, administered twice daily).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.